NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

Start Free »

Takeda Pharmaceutical Company Limited TAK | NYSE

$17.86 $0.00 | 0.00%

SIGNAL:

|2026-10-02 |F&G 43 |RSI 39.8

Add to favoritesFavorite

Company Overview:

Market Cap: $56.43B

Trailing PE: 0.3x

FWD PE *: 0.2x

Payout Ratio (TTM): —

52-Week Range: $12.99 - $19.10

* Forward PE is based on street estimates.

10 Year TAK Performance Metrics:

Total Return (with DRIP): -11.5% (-1.22% CAGR)

Total Return (no DRIP): -14.7% (-1.58% CAGR)

Share Price: -24.9% (-2.83% CAGR)

Yield on Cost (with DRIP): 3.05%

Total Invested: $10,000

Total Value (with DRIP): $8,849

Total Return $ (with DRIP): -$1,151

Dividend Increase: -0.5% (-0.16% CAGR)

Dividend Yield (FWD): 3.45% ($0.62)

TAK 10-yr Total Return ($10K invested)

1M 3M 6M YTD 1Y 3Y 5Y 10Y

TAK Share Price

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

TAK Price CAGR:1Y: 23.68%2Y: 11.68%5Y: 1.72%10Y: -2.83%

TAK Dividend Charts

TAK - Dividends

TAK Dividend CAGR:1Y: -2.90%2Y: 2.70%5Y: -0.16%10Y: -0.16%

TAK - Dividend Payout Ratio

TAK Dividend Payout Ratio CAGR:1Y: 13.41%2Y: -4.36%5Y: 6.70%10Y: 7.61%

TAK - Dividend to Free Cash Flow Ratio

TAK Dividend to FCF Ratio CAGR:1Y: 113,557.19%2Y: 1,255.79%5Y: 306.51%10Y: 91.82%

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

TAK Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

TAK - Revenue

TAK Revenue CAGR:1Y: 10.23%2Y: 0.49%5Y: 5.14%10Y: 10.89%

TAK - Earnings Per Share (EPS)

TAK EPS CAGR:1Y: -9.84%2Y: 8.48%5Y: -16.61%10Y: -5.69%

TAK - Net Income

🔓 See the full chart40% off right now · 7-day free trial

TAK Net Income CAGR:1Y: -8.84%2Y: 9.04%5Y: -3.83%10Y: 1.30%

TAK - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

TAK EBITDA CAGR:1Y: -23.20%2Y: -6.32%5Y: -5.04%10Y: 5.43%

TAK - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

TAK Free Cash Flow CAGR:1Y: -99.91%2Y: -92.31%5Y: -74.76%10Y: -43.18%

TAK - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

TAK Free Cash Flow / Share CAGR:1Y: -52.59%2Y: 85.33%5Y: -10.13%10Y: 7.35%

TAK - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

TAK Operating Income CAGR:1Y: 9.13%2Y: -4.25%5Y: -4.12%10Y: 2.79%

TAK - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

TAK Gross Profit CAGR:1Y: 12.63%2Y: 11.15%5Y: 2.80%10Y: 10.54%

TAK - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

TAK Shares Outstanding CAGR:1Y: 1.04%2Y: 0.49%5Y: 15.60%10Y: 7.41%

TAK - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

TAK Share Buybacks CAGR:1Y: -98.05%2Y: -26.85%5Y: -16.91%10Y: -26.19%

TAK - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

TAK Stock-Based Comp CAGR:1Y: 10.04%2Y: 8.73%5Y: 16.31%10Y: 0.00%

TAK - Expenses

🔓 See the full chart40% off right now · 7-day free trial

TAK Expenses CAGR:1Y: -28.32%2Y: -37.51%5Y: 4.94%10Y: 14.08%

TAK - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

TAK - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

TAK - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

TAK - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

TAK - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

TAK - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

TAK - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

TAK Actual Revenue CAGR:1Y: 10.23%2Y: 0.49%5Y: 5.14%10Y: 10.89%

TAK - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

TAK Actual EPS CAGR:1Y: -9.84%2Y: 8.48%5Y: -16.61%10Y: -5.69%

TAK - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

TAK Actual Net Income CAGR:1Y: -8.84%2Y: 9.04%5Y: -3.83%10Y: 1.30%

TAK - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

TAK Actual EBITDA CAGR:1Y: -23.20%2Y: -6.32%5Y: -5.04%10Y: 5.43%

Ratios, Profit Margins & Return on Capital:

TAK - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

TAK Net Profit Margin CAGR:1Y: -17.36%2Y: 8.52%5Y: -8.54%10Y: -8.65%

TAK - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

TAK Gross Profit Margin CAGR:1Y: 24.95%2Y: 10.60%5Y: -2.22%10Y: -0.32%

TAK - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

TAK Price to Earnings CAGR:1Y: 29.10%2Y: 2.08%5Y: 27.94%10Y: 7.50%

TAK - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

TAK Price To Sales Ratio CAGR:1Y: 5.54%2Y: 10.13%5Y: 16.75%10Y: -1.91%

TAK - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

TAK Return on Capital Employed CAGR:1Y: -3.04%2Y: -1.10%5Y: -7.21%10Y: -11.18%

TAK - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

TAK Return on Invested Capital CAGR:1Y: -18.91%2Y: -1.73%5Y: -8.08%10Y: -11.90%

TAK Dividends Info:

Annual Dividend: $0.61654

Forward Yield: 3.45%

Ex-Dividend Date: 2026-03-31

Lifetime Dividends / Share: $2.42

TAK Dividend History: Dates, Payments & Yield list

Below is a schedule of all TAK dividend payments, ex-dates, share price on the day of the payment as well as the annualized yield & forward yield

Ex-Date	Payment Date	Amount	Yield	Forward Yield	Price on Ex-Date
03/31/2026	07/06/2026	$0.308	3.33%	3.65%	$16.89
09/30/2025	12/11/2025	$0.322	4.4%	4.48%	$14.39
03/31/2025	07/07/2025	$0.276	3.71%	3.66%	$15.07
09/30/2024	12/12/2024	$0.326	4.59%	4.85%	$13.45
03/27/2024	07/08/2024	$0.292	4.12%	4.43%	$13.18
09/28/2023	12/11/2023	$0.319	4.09%	4.55%	$14.04
03/30/2023	07/10/2023	$0.310	3.79%	3.99%	$15.54
09/29/2022	12/12/2022	$0.270	2.08%	1.81%	$14.92

Projected Future Returns & Dividends for TAK

Based on past 10-year performance, here are TAK growth metrics:

Share price CAGR of -2.83%
Dividend CAGR of -0.16%

Using TAK CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	TAK (DRIP)	TAK - No DRIP
Current Price	$17.86	$17.86
Start Shares	559.91	559.91
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	788.43	559.91
Dividends Payment	$0.23	$0.23
Annual Dividends	$365	$259
Yield on cost	3.65%	2.59%
Share Price	$13.41	$13.41
Total Dividends	$3,570	$3,045
Final Value	$10,571	$10,552

Estimated Future Value + Dividends - TAK

NOTE: Above numbers are our estimate based on TAK's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Takeda Pharmaceutical Company Limited (TAK) had its IPO on 2010-01-05, and is traded on NYSE stock exchange.

Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.

TAK website: https://www.takeda.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

DCF Model — TAK

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $17.86

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →